Protalix Bio Therapeutics, Inc. PLX
We take great care to ensure that the data presented and summarized in this overview for Protalix BioTherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PLX
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$2.65 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$1.77 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.36 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$813,7940.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$795,0680.0% of portfolio
-
Morgan Stanley New York, NY462KShares$757,7500.0% of portfolio
-
State Street Corp Boston, MA444KShares$728,5510.0% of portfolio
-
Stratos Wealth Partners, Ltd.350KShares$574,0000.01% of portfolio
-
Black Rock Inc. New York, NY333KShares$546,4000.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA299KShares$489,6490.0% of portfolio
Latest Institutional Activity in PLX
Top Purchases
Top Sells
About PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Insider Transactions at PLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2025
|
Aharon Schwartz |
BUY
Open market or private purchase
|
Direct |
129,000
+29.86%
|
$129,000
$1.6 P/Share
|
|
Sep 23
2024
|
Eyal Rubin Sr. VP and CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
99,010
+12.89%
|
-
|
|
Apr 01
2024
|
Dror Bashan PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
263,960
+10.94%
|
-
|
|
Oct 19
2023
|
Dror Bashan PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
64,516
+20.11%
|
$64,516
$1.41 P/Share
|
|
Aug 15
2023
|
Yaron Naos Sr. VP, Operations |
BUY
Grant, award, or other acquisition
|
Indirect |
187,344
+48.26%
|
-
|
|
Aug 15
2023
|
Yael Hayon VP, Research & Development |
BUY
Grant, award, or other acquisition
|
Indirect |
35,115
+50.0%
|
-
|
|
Aug 15
2023
|
Eyal Rubin Sr. VP and CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
201,903
+26.16%
|
-
|
|
Aug 15
2023
|
Dror Bashan PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
800,000
+29.79%
|
-
|
|
Jan 03
2023
|
Aharon Schwartz |
BUY
Open market or private purchase
|
Direct |
110,000
+38.73%
|
$110,000
$1.42 P/Share
|
|
Apr 11
2022
|
Dror Bashan PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
68,000
+50.0%
|
$68,000
$1.5 P/Share
|
|
Feb 25
2022
|
Dror Bashan PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
637,531
+37.0%
|
-
|
|
Feb 25
2022
|
Eyal Rubin Sr. VP and CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
121,951
+24.89%
|
-
|
|
Jun 03
2021
|
Dexcel Pharma Technologies Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
857,506
-19.08%
|
$1,715,012
$2.25 P/Share
|
|
Jun 02
2021
|
Dexcel Pharma Technologies Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
61,211
-1.34%
|
$122,422
$2.56 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 129K shares |
|---|---|
| Grant, award, or other acquisition | 99K shares |